The Effect of Rotigotine Extended-Release Microspheres Alone or With Celecoxib on the Inflammatory Pain

Frontiers in Pharmacology
Keke LiFenghua Fu

Abstract

Clinical trials of rotigotine extended-release microspheres (RTGT-MS), which provides a sustained release of rotigotine for near 2 weeks in vivo, have been conducted in the treatment of Parkinson's disease (PD). This study was to investigate the analgesic effect of RTGT-MS, and to know whether RTGT-MS have synergistic interaction with non-steroidal anti-inflammatory drug, celecoxib. The inflammatory pain model of rats was prepared by carrageenan-induced paw edema. The thermal and mechanical stimuli were applied and the hindpaw withdrawal latency (HWL) response was evaluated. Treatment with RTGT-MS increased the HWL in a dose-dependent manner. The ED50 of RTGT-MS was 24.68 ± 1.02 mg/kg. Isobolographic analysis shows that the combination of RTGT-MS and celecoxib resulted in a synergistic antinociceptive effect. Further results demonstrated that antinociceptive effect of RTGT-MS was accompanied with that PKA, cAMP, COX-2, and PGE2 levels were decreased. Chlorpromazine, a dopamine receptor blocker, not only weakened the analgesic effect of RTGT-MS, but also increased the levels of cAMP, PKA, COX-2, and PGE2. These findings provide a rationale for the combination of RTGT-MS and celecoxib in the treatment of PD, which may reduce the ...Continue Reading

References

Jun 14, 1986·Lancet·N P QuinnC D Marsden
Aug 1, 1985·Pain·G D Schott
Jul 1, 1996·Movement Disorders : Official Journal of the Movement Disorder Society·B FordS Fahn
Oct 19, 1999·Brain Research. Brain Research Reviews·F TorreillesJ Torreilles
Jul 6, 2002·Pain·Ronald J Tallarida
Mar 21, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Kallol Ray ChaudhuriCharles W Olanow
Apr 2, 2008·Circulation·Scott D SolomonUNKNOWN Cross Trial Safety Assessment Group
Jun 3, 2009·Nature Reviews. Neurology·Blair Ford
Feb 27, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Blair Ford
Jun 11, 2011·European Journal of Pharmacology·Yoshihiro TadoriTetsuro Kikuchi
Dec 23, 2011·Parkinsonism & Related Disorders·Hong-Bo WenQun Xu
Jan 11, 2012·Movement Disorders : Official Journal of the Movement Disorder Society·Martijn P G BroenWim E J Weber
Feb 4, 2012·Journal of Pharmacological Sciences·Víctor Fernández-DueñasFrancisco Ciruela
Apr 26, 2012·Expert Opinion on Emerging Drugs·Santiago Perez-LloretOlivier Rascol
Oct 15, 2013·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·G DefazioA Berardelli
Feb 12, 2015·British Journal of Pharmacology·Jean-Martin BeaulieuRaul R Gainetdinov
Oct 8, 2015·International Psychogeriatrics·Xing-Jian LinWei-Guo Liu
Aug 16, 2017·Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Société Canadienne Des Sciences Pharmaceutiques·Fei ChenZhiyu Nie
Mar 10, 2018·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A AntoniniO Rascol
Aug 9, 2018·Frontiers in Neurology·Luigi Ferini-StrambiAndrea Galbiati
Jan 18, 2019·Movement Disorders : Official Journal of the Movement Disorder Society·Klaus SeppiUNKNOWN the collaborators of the Parkinson's Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders So
Apr 9, 2019·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Huaiyou LvFenghua Fu
Jul 25, 2019·Expert Opinion on Pharmacotherapy·Marco Krasselt, Christoph Baerwald

❮ Previous
Next ❯

Citations

Mar 31, 2021·Current Opinion in Supportive and Palliative Care·Katarina RukavinaKirsty Bannister
May 20, 2021·Current Opinion in Supportive and Palliative Care·Katarina RukavinaKirsty Bannister

❮ Previous
Next ❯

Methods Mentioned

BETA
scanning electron microscopy
ELISA

Software Mentioned

GraphPad

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Deutsche medizinische Wochenschrift
R FuxC H Gleiter
Reumatizam
D Babić-Naglić
Revista de medicina de la Universidad de Navarra
E CaballeroJ Honorato
Clinical Journal of Oncology Nursing
M E O'Rourke
Journal of the Royal Society of Medicine
Raymond Cheung, Simon Lowry
© 2021 Meta ULC. All rights reserved